AIM ImmunoTech (AIM) Equity Average (2018 - 2025)
Historic Equity Average for ImmunoTech (AIM) over the last 10 years, with Q3 2025 value amounting to -$6.3 million.
- ImmunoTech's Equity Average fell 24003.77% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.3 million, marking a year-over-year decrease of 24003.77%. This contributed to the annual value of $4.5 million for FY2024, which is N/A changed from last year.
- Per ImmunoTech's latest filing, its Equity Average stood at -$6.3 million for Q3 2025, which was down 24003.77% from -$5.2 million recorded in Q2 2025.
- In the past 5 years, ImmunoTech's Equity Average ranged from a high of $26.4 million in Q3 2023 and a low of -$6.3 million during Q3 2025
- In the last 3 years, ImmunoTech's Equity Average had a median value of $4.5 million in 2024 and averaged $5.2 million.
- Per our database at Business Quant, ImmunoTech's Equity Average tumbled by 8290.76% in 2024 and then crashed by 24003.77% in 2025.
- Quarter analysis of 3 years shows ImmunoTech's Equity Average stood at $16.4 million in 2023, then plummeted by 95.16% to $795000.0 in 2024, then plummeted by 893.9% to -$6.3 million in 2025.
- Its Equity Average stands at -$6.3 million for Q3 2025, versus -$5.2 million for Q2 2025 and -$2.6 million for Q1 2025.